CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
SM Albelda - Nature Reviews Clinical Oncology, 2024 - nature.com
Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …
Next‐generation chimeric antigen receptors for T‐and natural killer‐cell therapies against cancer
Adoptive cellular therapy using chimeric antigen receptor (CAR) T cells has led to a
paradigm shift in the treatment of various hematologic malignancies. However, the broad …
paradigm shift in the treatment of various hematologic malignancies. However, the broad …
Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint …
AJ Schoenfeld, SM Lee, B Doger de Speville… - Cancer …, 2024 - aacrjournals.org
In this phase 2 multicenter study, we evaluated the efficacy and safety of lifileucel (LN-145),
an autologous tumor-infiltrating lymphocyte cell therapy, in patients with metastatic non …
an autologous tumor-infiltrating lymphocyte cell therapy, in patients with metastatic non …
Molecular Frontiers in Melanoma: Pathogenesis, Diagnosis, and Therapeutic Advances
HJ Kim, YH Kim - International Journal of Molecular Sciences, 2024 - mdpi.com
Melanoma, a highly aggressive skin cancer, is characterized by rapid progression and high
mortality. Recent advances in molecular pathogenesis have shed light on genetic and …
mortality. Recent advances in molecular pathogenesis have shed light on genetic and …
Development of Personalized Strategies for Precisely Battling Malignant Melanoma
AJ Isaak, GGR Clements, RGM Buenaventura… - International Journal of …, 2024 - mdpi.com
Simple Summary Precision oncology is emerging as a viable option to improve survival in
patients who fail to remain disease-free even after the employment of currently available …
patients who fail to remain disease-free even after the employment of currently available …
ALKemy to enhance chimeric antigen receptor T cell immunotherapy for neuroblastoma
M Ruella - Cancer Cell, 2023 - cell.com
Chimeric antigen receptor (CAR) T cell immunotherapy in solid cancer is severely limited by
the absence of ideal targets. In this issue of Cancer Cell, Bergaggio et al. find that anaplastic …
the absence of ideal targets. In this issue of Cancer Cell, Bergaggio et al. find that anaplastic …
Adoptive cell immunotherapy for breast cancer: harnessing the power of immune cells
X Li, Y Zhu, J Yi, Y Deng, B Lei… - Journal of Leukocyte …, 2024 - academic.oup.com
Breast cancer is the most prevalent malignant neoplasm worldwide, necessitating the
development of novel therapeutic strategies owing to the limitations posed by conventional …
development of novel therapeutic strategies owing to the limitations posed by conventional …
Tumor-infiltrating lymphocytes for melanoma immunotherapy
Oncological routine has incorporated the regular use of monoclonal antibodies targeting
checkpoints of T cell function such as ipilimumab, which blocks cytotoxic T-lymphocyte …
checkpoints of T cell function such as ipilimumab, which blocks cytotoxic T-lymphocyte …
Advances in preclinical TCR characterization: leveraging cell avidity to identify functional TCRs
A Carr, LM Mateyka, SJC Scheu, A Bici… - Biological …, 2024 - degruyter.com
T-cell therapy has emerged as an effective approach for treating viral infections and cancers.
However, a significant challenge is the selection of T-cell receptors (TCRs) that exhibit the …
However, a significant challenge is the selection of T-cell receptors (TCRs) that exhibit the …
Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia
Despite advancements, acute myeloid leukemia (AML) remains unconquered by current
therapies. Evidence of immune evasion during AML progression, such as HLA loss and T …
therapies. Evidence of immune evasion during AML progression, such as HLA loss and T …